Compass Pathways is a biotechnology company founded in 2016, focused on developing new treatment pathways for mental health conditions. Its primary focus is COMP360, an investigational synthetic psilocybin therapy currently in a global phase 3 clinical programme for treatment-resistant depression. The treatment has received FDA Breakthrough Therapy designation and UK Innovative Licensing and Access Pathway (ILAP) designation. The company is also conducting research into the potential of COMP360 for post-traumatic stress disorder and anorexia nervosa.
The company's technical work spans biotechnology, pharmaceutical research, and clinical trials. It maintains offices in London and New York City. The organisation's culture is influenced by personal experience with mental health challenges, which informs a stated commitment to accelerating patient access to evidence-based innovation.
